ACS-NETRİN-1: The Role of Netrin -1 in Acute Coronary Syndrome

Sponsor

Aksaray University Training and Research Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT04027127

Collaborator

(none)

238

Enrollment

Arms

Actual Duration (Months)

Study Details

Study Description

Brief Summary

In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.

Condition or Disease	Intervention/Treatment	Phase
Acute Coronary Syndrome	Other: netrin-1 value on admission to hospital	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

238 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Intervention Model Description:

PATIENT AND CONTROL GROUP will be divided into two.PATIENT AND CONTROL GROUP will be divided into two.

Masking:

Single (Participant)

Masking Description:

Patient group; Those diagnosed with ACS over 18 years of age, planned angiography and accepted angiography. The control group consisted of volunteers without disease.

Primary Purpose:

Diagnostic

Official Title:

The Effect of Serum Netrin-1 Levels on Diagnosis and Prognosis in Patients Presenting to the Emergency Department With Acute Coronary Syndrome

Actual Study Start Date :

Sep 15, 2013

Actual Primary Completion Date :

Aug 15, 2014

Actual Study Completion Date :

Jun 15, 2018

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: ACS GRUP Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared. GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared.	Other: netrin-1 value on admission to hospital
Active Comparator: plasebo grup It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.	Other: netrin-1 value on admission to hospital

Arm

Intervention/Treatment

Active Comparator: ACS GRUP

Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared. GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared.

Other: netrin-1 value on admission to hospital

Active Comparator: plasebo grup

It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.

Other: netrin-1 value on admission to hospital

Outcome Measures

Primary Outcome Measures

serum netrin-1 value [30 minute]
Netrin-1 in plasma was measured by enzyme-linked immunosorbent assay (ELISA) (Mybıosource MBS044526 ) All assays were performed in duplicate. Plasma Netrin-1 is expressed in picograms (pg) per mg.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Patients over the age of 18
diagnose ACS
patients undergoing angiography

Exclusion Criteria:

CVE history
Neurological disease
Pregnancy and Lactation
Liver failure
Diagnosed malignity
Use of anticonvulsant and nephrotoxic medication
Chronic kidney disease
Not having angiography
Developing acute renal failure after angiography
Patients who rejected to participate were excluded.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Aksaray University Training and Research Hospital

Investigators

Study Director: Hüseyin Mutlu, MD, Aksaray/Turkey

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

huseyin mutlu, Asst. Prof. Dr. Principal Investigator, Aksaray University Training and Research Hospital

ClinicalTrials.gov Identifier:

NCT04027127

Other Study ID Numbers:

aksaray 2013-23

First Posted:

Jul 19, 2019

Last Update Posted:

Jul 19, 2019

Last Verified:

Jul 1, 2019

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by huseyin mutlu, Asst. Prof. Dr. Principal Investigator, Aksaray University Training and Research Hospital

netrin-1

acs

reperfuzion

Additional relevant MeSH terms:

Acute Coronary Syndrome

Syndrome

Study Results

No Results Posted as of Jul 19, 2019